一种病毒样颗粒疫苗在人体内引发针对所有基孔肯雅病毒基因型的广泛中和抗体反应。
A Virus-Like Particle Vaccine Elicits Broad Neutralizing Antibody Responses in Humans to All Chikungunya Virus Genotypes.
作者信息
Goo Leslie, Dowd Kimberly A, Lin Tsai-Yu, Mascola John R, Graham Barney S, Ledgerwood Julie E, Pierson Theodore C
机构信息
Viral Pathogenesis Section, Laboratory of Viral Diseases.
Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland.
出版信息
J Infect Dis. 2016 Nov 15;214(10):1487-1491. doi: 10.1093/infdis/jiw431. Epub 2016 Sep 21.
Abstract
Chikungunya virus (CHIKV) is an alphavirus that has emerged as a global health burden. There are 3 CHIKV genotypes: Asian, West African, and Eastern/Central/South African. No licensed CHIKV vaccine is available, and whether the antibody response elicited by one genotype can neutralize heterologous genotypes is unclear. We assessed neutralizing antibody (NAb) responses of volunteers in a phase 1 study of a CHIKV vaccine against 9 viral strains representing all 3 genotypes. Minimal differences in vaccine-elicited NAb responses were observed among genotypes, suggesting that vaccination with a single CHIKV strain can elicit cross-protective NAbs against all 3 genotypes.
摘要
基孔肯雅病毒（CHIKV）是一种已成为全球健康负担的甲病毒。CHIKV有3种基因型：亚洲型、西非型和东非/中非/南非型。目前尚无获得许可的CHIKV疫苗，且一种基因型引发的抗体反应能否中和异源基因型尚不清楚。我们在一项CHIKV疫苗1期研究中评估了志愿者针对代表所有3种基因型的9种病毒株的中和抗体（NAb）反应。各基因型之间在疫苗引发的NAb反应中观察到的差异极小，这表明用单一CHIKV毒株进行疫苗接种可引发针对所有3种基因型的交叉保护性NAb。
相似文献
1
A Virus-Like Particle Vaccine Elicits Broad Neutralizing Antibody Responses in Humans to All Chikungunya Virus Genotypes.一种病毒样颗粒疫苗在人体内引发针对所有基孔肯雅病毒基因型的广泛中和抗体反应。
J Infect Dis. 2016 Nov 15;214(10):1487-1491. doi: 10.1093/infdis/jiw431. Epub 2016 Sep 21.
2
Antigenic Variation of East/Central/South African and Asian Chikungunya Virus Genotypes in Neutralization by Immune Sera.东非/中非/南非和亚洲基孔肯雅病毒基因型在免疫血清中和作用下的抗原变异
PLoS Negl Trop Dis. 2016 Aug 29;10(8):e0004960. doi: 10.1371/journal.pntd.0004960. eCollection 2016 Aug.
3
Whole-Inactivated and Virus-Like Particle Vaccine Strategies for Chikungunya Virus.基孔肯雅病毒的全灭活疫苗和病毒样颗粒疫苗策略
J Infect Dis. 2016 Dec 15;214(suppl 5):S497-S499. doi: 10.1093/infdis/jiw352.
4
Vaccination with a chikungunya virus-like particle vaccine exacerbates disease in aged mice.接种基孔肯雅病毒样颗粒疫苗会使老年小鼠的病情恶化。
PLoS Negl Trop Dis. 2019 Apr 26;13(4):e0007316. doi: 10.1371/journal.pntd.0007316. eCollection 2019 Apr.
5
Broad and long-lasting immune protection against various Chikungunya genotypes demonstrated by participants in a cross-sectional study in a Cambodian rural community.在柬埔寨农村社区进行的一项横断面研究中，参与者表现出对各种基孔肯雅病毒基因型的广泛和持久的免疫保护。
Emerg Microbes Infect. 2018 Feb 7;7(1):13. doi: 10.1038/s41426-017-0010-0.
6
Evaluation of recombinant E2 protein-based and whole-virus inactivated candidate vaccines against chikungunya virus.评估基于重组 E2 蛋白和全病毒灭活的候选登革热病毒疫苗。
Vaccine. 2012 Sep 21;30(43):6142-9. doi: 10.1016/j.vaccine.2012.07.072. Epub 2012 Aug 8.
7
Co-Immunization With CHIKV VLP and DNA Vaccines Induces a Promising Humoral Response in Mice.二价嵌合病毒样颗粒和 DNA 疫苗共免疫诱导小鼠产生有前景的体液免疫应答。
Front Immunol. 2021 Mar 24;12:655743. doi: 10.3389/fimmu.2021.655743. eCollection 2021.
8
Effect of a Chikungunya Virus-Like Particle Vaccine on Safety and Tolerability Outcomes: A Randomized Clinical Trial.一种基孔肯雅病毒样颗粒疫苗的安全性和耐受性结果：一项随机临床试验。
JAMA. 2020 Apr 14;323(14):1369-1377. doi: 10.1001/jama.2020.2477.
9
A recombinant measles vaccine expressing chikungunya virus-like particles is strongly immunogenic and protects mice from lethal challenge with chikungunya virus.一种表达基孔肯雅病毒样颗粒的重组麻疹疫苗具有很强的免疫原性，可保护小鼠免受基孔肯雅病毒的致死性挑战。
Vaccine. 2013 Aug 12;31(36):3718-25. doi: 10.1016/j.vaccine.2013.05.086. Epub 2013 Jun 4.
10
Chikungunya virus-like particles are more immunogenic in a lethal AG129 mouse model compared to glycoprotein E1 or E2 subunits.与糖蛋白 E1 或 E2 亚单位相比，基孔肯雅病毒样颗粒在致死性 AG129 小鼠模型中具有更高的免疫原性。
Vaccine. 2013 Dec 9;31(51):6092-6. doi: 10.1016/j.vaccine.2013.09.045. Epub 2013 Oct 5.
引用本文的文献
1
Chikungunya virus and other emerging arthritogenic alphaviruses.基孔肯雅病毒及其他新出现的致关节炎甲病毒
Nat Rev Microbiol. 2025 May 7. doi: 10.1038/s41579-025-01177-8.
2
Cross-neutralizing activity of the chikungunya vaccine VLA1553 against three prevalent chikungunya lineages.基孔肯雅疫苗VLA1553对三种流行的基孔肯雅病毒谱系的交叉中和活性。
Emerg Microbes Infect. 2025 Dec;14(1):2469653. doi: 10.1080/22221751.2025.2469653. Epub 2025 Mar 10.
3
A vaccine candidate based on baculovirus displaying chikungunya virus E1-E2 envelope confers protection against challenge in mice.基于杆状病毒展示的基孔肯雅病毒 E1-E2 包膜的疫苗候选物可在小鼠中提供针对挑战的保护。
J Virol. 2024 Nov 19;98(11):e0101724. doi: 10.1128/jvi.01017-24. Epub 2024 Oct 23.
4
Chikungunya Virus Vaccines: A Review of IXCHIQ and PXVX0317 from Pre-Clinical Evaluation to Licensure.基孔肯雅病毒疫苗：从临床前评估到许可的 IXCHIQ 和 PXVX0317 综述。
BioDrugs. 2024 Nov;38(6):727-742. doi: 10.1007/s40259-024-00677-y. Epub 2024 Sep 18.
5
Chikungunya: a decade of burden in the Americas.基孔肯雅热：美洲十年的负担
Lancet Reg Health Am. 2024 Jan 8;30:100673. doi: 10.1016/j.lana.2023.100673. eCollection 2024 Feb.
6
A chikungunya virus-like particle vaccine induces broadly neutralizing and protective antibodies against alphaviruses in humans.一种基孔肯雅病毒样颗粒疫苗可诱导人类针对甲病毒产生广泛中和和保护抗体。
Sci Transl Med. 2023 May 17;15(696):eade8273. doi: 10.1126/scitranslmed.ade8273.
7
Chikungunya fever.基孔肯雅热。
Nat Rev Dis Primers. 2023 Apr 6;9(1):17. doi: 10.1038/s41572-023-00429-2.
8
Chikungunya Virus: Priority Pathogen or Passing Trend?基孔肯雅病毒：重点病原体还是一时流行趋势？
Vaccines (Basel). 2023 Mar 1;11(3):568. doi: 10.3390/vaccines11030568.
9
Comparative Efficacy of Mayaro Virus-Like Particle Vaccines Produced in Insect or Mammalian Cells.昆虫细胞或哺乳动物细胞生产的马亚罗病毒样颗粒疫苗的比较效力。
J Virol. 2023 Mar 30;97(3):e0160122. doi: 10.1128/jvi.01601-22. Epub 2023 Mar 8.
10
Understanding the Biology and Immune Pathogenesis of Chikungunya Virus Infection for Diagnostic and Vaccine Development.了解基孔肯雅热病毒感染的生物学和免疫发病机制，用于诊断和疫苗开发。
Viruses. 2022 Dec 23;15(1):48. doi: 10.3390/v15010048.
本文引用的文献
1
Rapid and Long-Term Immunity Elicited by DNA-Encoded Antibody Prophylaxis and DNA Vaccination Against Chikungunya Virus.DNA编码抗体预防和针对基孔肯雅病毒的DNA疫苗接种引发的快速和长期免疫
J Infect Dis. 2016 Aug 1;214(3):369-78. doi: 10.1093/infdis/jiw111. Epub 2016 Mar 21.
2
Interspecies transmission and chikungunya virus emergence.种间传播与基孔肯雅病毒的出现。
Curr Opin Virol. 2016 Feb;16:143-150. doi: 10.1016/j.coviro.2016.02.007. Epub 2016 Mar 14.
3
Factors responsible for the emergence of arboviruses; strategies, challenges and limitations for their control.虫媒病毒出现的相关因素；其控制的策略、挑战与局限
Emerg Microbes Infect. 2015 Mar;4(3):e18. doi: 10.1038/emi.2015.18. Epub 2015 Mar 25.
4
Therapeutics and vaccines against chikungunya virus.针对基孔肯雅病毒的治疗方法和疫苗。
Vector Borne Zoonotic Dis. 2015 Apr;15(4):250-7. doi: 10.1089/vbz.2014.1681.
5
Safety and tolerability of chikungunya virus-like particle vaccine in healthy adults: a phase 1 dose-escalation trial.在健康成年人中，基孔肯雅病毒样颗粒疫苗的安全性和耐受性：一项 1 期剂量递增试验。
Lancet. 2014 Dec 6;384(9959):2046-52. doi: 10.1016/S0140-6736(14)61185-5. Epub 2014 Aug 14.
6
Chikungunya in the Americas.美洲的基孔肯雅热
Lancet. 2014 Feb 8;383(9916):514. doi: 10.1016/S0140-6736(14)60185-9.
7
Development of a highly protective combination monoclonal antibody therapy against Chikungunya virus.开发针对基孔肯雅病毒的高度保护性组合单克隆抗体疗法。
PLoS Pathog. 2013;9(4):e1003312. doi: 10.1371/journal.ppat.1003312. Epub 2013 Apr 18.
8
Structural analyses at pseudo atomic resolution of Chikungunya virus and antibodies show mechanisms of neutralization.基孔肯雅病毒和抗体的准原子分辨率结构分析揭示了中和机制。
Elife. 2013 Apr 2;2:e00435. doi: 10.7554/eLife.00435.
9
A virus-like particle vaccine for epidemic Chikungunya virus protects nonhuman primates against infection.一种类似病毒的颗粒疫苗可预防基孔肯雅热病毒，保护非人灵长类动物免受感染。
Nat Med. 2010 Mar;16(3):334-8. doi: 10.1038/nm.2105. Epub 2010 Jan 28.
10
A single mutation in chikungunya virus affects vector specificity and epidemic potential.基孔肯雅病毒的一个单一突变会影响载体特异性和流行潜力。
PLoS Pathog. 2007 Dec;3(12):e201. doi: 10.1371/journal.ppat.0030201.
Zotero 插件